MarketBeat
09 May 2026, 04:09 UTC · 19w ago
Verdict
Headline takes no side. We score STOK +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Stoke Therapeutics remains on track to complete Phase 3 EMPEROR enrollment in June, targeting a mid-2027 data readout and a rolling NDA submission starting in Q1 2027.
More positive than 99% of claims this week
Four-year open-label extension data showed median major motor seizure frequency reductions of 59% to 91% and statistically significant improvements in Vineland-3 behavioral and cognitive subdomains.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 98% of claims this week
No patients have discontinued treatment in the Phase 3 EMPEROR study to date, and no new safety findings have emerged after over five years and 850 doses of clinical data.
More positive than 93% of claims this week
Stoke is planning for a potential U.S. launch in late 2027 or early 2028, targeting an addressable population of approximately 6,000 patients through a lean commercial infrastructure.
More positive than 86% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
Positive four-year data showing durable seizure reduction and cognitive improvement, with Phase 3 enrollment on track.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
48m ago
−20.6%
Price is moving against the score
$26.11 vs $32.89 close before publication (May 8) · not market-adjusted
STOK chart →
